All Search Results
-
Beat Childhood Cancer Specimen Banking and Data Registry
Specimen Banking With Clinical and Genomic Data Registry With the Establishment of Tumor Models for Pediatric Cancers
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Subjects with Moderately to Severely Active Ulcerative Colitis
-
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
A Phase II study of Naxitamab added to induction Therapy for Subjects with Newly Diagnosed High Risk Neuroblastoma
-
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors
Walking Juntos: Developing and Testing a Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
-
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors
-
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
-
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
-
CIBMTR Research Database
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
-
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old With First Relapse
